Annual Drug Patent Expirations for RENAGEL
Renagel is a drug marketed by Genzyme and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge.
Drug patent litigation for RENAGEL.
This drug has thirty-eight patent family members in thirty-one countries.
The generic ingredient in RENAGEL is sevelamer hydrochloride. Two suppliers are listed for this compound. Additional details are available on the sevelamer hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
